Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

34.34
+0.68772.04%
Post-market: 33.65-0.6880-2.00%16:04 EDT
Volume:2K
Turnover:54.52K
Market Cap:13.74M
PE:- -
High:34.34
Open:33.65
Low:33.65
Close:33.65
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.76
T/O Rate:0.40%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Health Care up on Defensive Bias

Dow Jones
·
Oct 08

3 ‘Strong Buy’ Dividend Aristocrat Stocks on Analysts’ Watch List

TIPRANKS
·
Oct 08

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 08

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Dow Jones
·
Oct 08

How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)

Simply Wall St.
·
Oct 08

Sector Update: Healthcare

MT Newswires Live
·
Oct 08

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Oct 08

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Early notable gainers among liquid option names on October 7th

TIPRANKS
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

Edwards Lifesciences Price Target Announced at $110.00/Share by Barclays

Dow Jones
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07